Evaluating Patient and Provider Preferences for a Once-Weekly Basal Insulin in Adults with Type 2 Diabetes

References

• Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020;10(1):107–111. doi:10.2991/jegh.k.191028.001
   PubMed Web of Science ®Google Scholar
• National Diabetes Statistics Report website; 2002. Available from: https://www.cdc.gov/diabetes/data/statistics-report/index.html. Accessed September 21, 2023.
   Google Scholar
• Fang M, Wang D, Coresh J, Selvin E. Undiagnosed Diabetes in U.S. Adults: prevalence and Trends. Diabetes Care. 2022;45(9):1994–2002. doi:10.2337/dc22-0242
   PubMed Web of Science ®Google Scholar
• Laiteerapong N, Ham SA, Gao Y, et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care. 2019;42(3):416–426. doi:10.2337/dc17-1144
   PubMed Web of Science ®Google Scholar
• ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140–s157. doi:10.2337/dc23-S009
   PubMedGoogle Scholar
• Yavuz DG, Ozcan S, Deyneli O. Adherence to insulin treatment in insulin-naïve type 2 diabetic patients initiated on different insulin regimens. Patient Prefer Adherence. 2015;9:1225–1231. doi:10.2147/ppa.S87935
   PubMed Web of Science ®Google Scholar
• United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995;310(6972):83–88.
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (Dawn) study. Diabetes Care. 2005;28(11):2673–2679. doi:10.2337/diacare.28.11.2673
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Jackson RA. What’s so tough about taking insulin? Addressing the problem of psychological insulin resistance in type 2 diabetes. Clin Diabetes. 2004;22(3):147–151.
   Google Scholar
• Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab. 2018;20(3):488–496. doi:10.1111/dom.13132
   PubMed Web of Science ®Google Scholar
• Blumer I, Clement M. Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges. Clin. Ther. 2017;39(8, Supplement 2):S1–S11. doi:10.1016/j.clinthera.2016.09.020
   PubMed Web of Science ®Google Scholar
• Harris SB, Kapor J, Lank CN, Willan AR, Houston T. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician. 2010;56(12):e418–24.
   PubMed Web of Science ®Google Scholar
• Kerr D, Warshaw H. Clouds and Silver Linings: COVID-19 Pandemic Is an Opportune Moment to Democratize Diabetes Care Through Telehealth. J Diabetes Sci Technol. 2020;14(6):1107–1110. doi:10.1177/1932296820963630
   PubMedGoogle Scholar
• Kerr D, Edelman S, Vespasiani G, Khunti K. New Digital Health Technologies for Insulin Initiation and Optimization for People With Type 2 Diabetes. Endocr Pract. 2022;28(8):811–821. doi:10.1016/j.eprac.2022.04.006
   PubMed Web of Science ®Google Scholar
• Perez-Nieves M, Boye KS, Kiljanski J, Cao D, Lage MJ. Adherence to Basal Insulin Therapy Among People with Type 2 Diabetes: A Retrospective Cohort Study of Costs and Patient Outcomes. Diabetes Ther. 2018;9(3):1099–1111. doi:10.1007/s13300-018-0421-5
   PubMed Web of Science ®Google Scholar
• Sarbacker GB, Urteaga EM. Adherence to Insulin Therapy. Diabetes Spectr. 2016;29(3):166–170. doi:10.2337/diaspect.29.3.166
   PubMedGoogle Scholar
• Brod M, Rana A, Barnett AH. Adherence patterns in patients with type 2 diabetes on basal insulin analogues: missed, mistimed and reduced doses. Curr Med Res Opin. 2012;28(12):1933–1946. doi:10.1185/03007995.2012.743458
   PubMed Web of Science ®Google Scholar
• Robinson S, Newson RS, Liao B, Kennedy-Martin T, Battelino T. Missed and mistimed insulin doses in people with diabetes: a systematic literature review. Diabetes Technol. Ther. 2021;23(12):844–856.
   PubMed Web of Science ®Google Scholar
• Rolla A. Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety. Am J Med. 2008;121(6 Suppl):S9–s19. doi:10.1016/j.amjmed.2008.03.022
   PubMed Web of Science ®Google Scholar
• Boye K, Ross M, Mody R, Konig M, Gelhorn H. Patients’ preferences for once-daily oral versus once-weekly injectable diabetes medications: the REVISE study. Diabetes Obes Metab. 2021;23(2):508–519. doi:10.1111/dom.14244
   PubMed Web of Science ®Google Scholar
• Boye KS, Jordan JB, Malik RE, Currie BM, Matza LS. Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments. Diabetes Therapy. 2021;12(9):2387–2403. doi:10.1007/s13300-021-01097-9
   PubMed Web of Science ®Google Scholar
• Flood EM, Bell KF, de la Cruz MC, Ginchereau-Sowell FM. Patient preferences for diabetes treatment attributes and drug classes. Curr Med Res Opin. 2017;33(2):261–268. doi:10.1080/03007995.2016.1253553
   PubMed Web of Science ®Google Scholar
• King A, Rajpura J, Liang Y, Paprocki Y, Uzoigwe C. Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease. Curr. Med. Res. Opin. 2022;38(11):1831–1840. doi:10.1080/03007995.2022.2125259
   PubMed Web of Science ®Google Scholar
• Tomaszewski KJ, Allen A, Mocarski M, et al. Divergence in perceptions of diabetes control among patients with type 2 diabetes mellitus treated with basal insulin and health care professionals: results from the US Perceptions of Control (POC-US) study. Patient Prefer Adherence. 2019;13:761–773. doi:10.2147/ppa.S194598
   PubMed Web of Science ®Google Scholar
• Noben CYG, Stammen LA, Vaassen S, et al. Discrete choice experiment on educating value-based healthcare. Postgraduate Medi J. 2020;97(1150):515–520. doi:10.1136/postgradmedj-2019-137190
   PubMed Web of Science ®Google Scholar
• Garcia-Dominguez JM, Muñoz D, Comellas M, Gonzalbo I, Lizán L, Polanco Sánchez C. Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment. Patient Prefer Adherence. 2016;10:1945–1956. doi:10.2147/ppa.S114619
   PubMed Web of Science ®Google Scholar
• Stewart KD, Johnston JA, Matza LS, et al. Preference for pharmaceutical formulation and treatment process attributes. Patient Prefer Adherence. 2016;10:1385–1399. doi:10.2147/ppa.S101821
   PubMed Web of Science ®Google Scholar
• van Heuckelum M, Mathijssen EG, Vervloet M, et al. Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment. Patient Prefer Adherence. 2019;13:1199–1211. doi:10.2147/ppa.S204111
   PubMed Web of Science ®Google Scholar
• Lingvay I, Asong M, Desouza C, et al. Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: the ONWARDS 3 Randomized Clinical Trial. JAMA. 2023;330(3):228–237. doi:10.1001/jama.2023.11313
   PubMed Web of Science ®Google Scholar
• Philis-Tsimikas A, Asong M, Franek E, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol. 2023;11(6):414–425. doi:10.1016/s2213-8587(23)00093-1
   PubMedGoogle Scholar
• Philis-Tsimikas A, Bajaj HS, Begtrup K, et al. Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes. Diabetes Obes Metab. 2023;25(2):331–341. doi:10.1111/dom.14871
   PubMed Web of Science ®Google Scholar
• Singh AK, Singh A, Singh R, Misra A. Once-weekly basal insulin icodec: Looking ONWARDS from pharmacology to clinical trials. Diabetes Metab Syndr. 2022;16(9):102615. doi:10.1016/j.dsx.2022.102615
   PubMed Web of Science ®Google Scholar
• Savarese G, Sharma A, Pang C, Wood R, Soleymanlou N. Patient preferences for newer oral therapies in type 2 diabetes. Int J Cardiol. 2023;371:526–532. doi:10.1016/j.ijcard.2022.09.009
   PubMed Web of Science ®Google Scholar
• Ozdemir S, Baid D, Verghese NR, et al. Patient Preferences for Medications in Managing Type 2 Diabetes Mellitus: A Discrete Choice Experiment. Value Health. 2020;23(7):842–850. doi:10.1016/j.jval.2020.01.023
   PubMed Web of Science ®Google Scholar
• Liu S, Liu J, Si L, et al. Patient preferences for anti-hyperglycaemic medication for type 2 diabetes mellitus in China: findings from a national survey. BMJ Glob Health. 2023;8(4):56.
   Web of Science ®Google Scholar
• Huang Y, Huang Q, Xu A, Lu M, Xi X. Patient Preferences for Diabetes Treatment Among People With Type 2 Diabetes Mellitus in China: A Discrete Choice Experiment. Front Public Health. 2021;9:782964. doi:10.3389/fpubh.2021.782964
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Zhang JY, Shang T, Mehta C, Kerr D. Pharmacoadherence: An Opportunity for Digital Health to Inform the Third Dimension of Pharmacotherapy for Diabetes. J Diabetes Sci Technol. 2021;15(1):177–183. doi:10.1177/1932296820973185
   PubMedGoogle Scholar
• Rutten GEHM, Vugt HV, Koning E. Person-centered diabetes care and patient activation in people with type 2 diabetes. BMJ Open Diabetes Res Care. 2020;8(2):e001926. doi:10.1136/bmjdrc-2020-001926
   PubMed Web of Science ®Google Scholar
• Pagidipati NJ, Nelson AJ, Kaltenbach LA, et al. Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2023;329(15):1261–1270. doi:10.1001/jama.2023.2854
   PubMed Web of Science ®Google Scholar
• Seng JJB, Monteiro AY, Kwan YH, et al. Population segmentation of type 2 diabetes mellitus patients and its clinical applications - A scoping review. BMC Med. Res. Method. 2021;21(1):49. doi:10.1186/s12874-021-01209-w
   PubMed Web of Science ®Google Scholar
• Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6(5):361–369. doi:10.1016/S2213-8587(18)30051-2
   PubMed Web of Science ®Google Scholar
• Davis J, Fischl AH, Beck J, et al. 2022 National Standards for Diabetes Self-Management Education and Support. Diabetes Care. 2022;45(2):484–494. doi:10.2337/dc21-2396
   PubMed Web of Science ®Google Scholar
• World Health Organization. First-ever global coverage targets for diabetes adopted at the 75th World Health Assembly. Available from: https://www.who.int/news-room/feature-stories/detail/first-ever-global-coverage-targets-for-diabetes-adopted-at-the-75-th-world-health-assembly. Accessed February 1, 2024.
   Google Scholar
• Wei W, Zhao S, Fu SL, et al. The Association of Hypoglycemia Assessed by Continuous Glucose Monitoring With Cardiovascular Outcomes and Mortality in Patients With Type 2 Diabetes. Front Endocrinol. 2019;10:536. doi:10.3389/fendo.2019.00536
   PubMed Web of Science ®Google Scholar